Search - tctmd.com

Displaying 21 - 40 of 68

Sort: Relevancy | Date

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

News Daily News

Según un Meta Análisis en Red el Riesgo de Trombosis del Andamiaje con el BVS Absorb es Mayor que con Otros Stents

Michael O'Riordan

June 06, 2016

News Daily News

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Michael O'Riordan

June 06, 2016

News Conference News EuroPCR 2016

Reassuring Registry Data Suggest Scaffold Thrombosis Rates with BVS Declining

Michael O'Riordan

May 17, 2016

News Industry News

Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial Against Xience

December 08, 2015

News Industry News

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

October 14, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

Presenter: Ioanna Kosmidou, Bernard R. Chevalier

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Bernard Chevalier

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Industry News

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

September 01, 2015

Advertisement

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Según un Meta Análisis en Red el Riesgo de Trombosis del Andamiaje con el BVS Absorb es Mayor que con Otros Stents

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Reassuring Registry Data Suggest Scaffold Thrombosis Rates with BVS Declining

Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial Against Xience

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content